Drug Trial Radar · NCT03597399
A Patient Registry Study for Patients Treated With Voretigene Neparvovec in US
Last checked: Nov 20, 2026Latest source record: Sep 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
87
Actual
Start
Jan 10, 2019
Primary completion
Jun 30, 2025
Study completion Jun 30, 2025
Sponsor
- Lead sponsor
- Spark Therapeutics, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jul 24, 2018
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to collect long-term safety information (i.e., for 5 years after treatment) associated with voretigene neparvovec-rzyl (vector and/or transgene), its subretinal injection procedure, the concomitant use of corticosteroids, or a combination of these procedures and products. The enrollment period will last for two years from the first treatment following product approval (through 31March2020) and include a minimum of 40 patients.
Conditions
- Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy
Interventions
AAV2-hRPE65v2,voretigene neparvovec-rzylBiological
Subretinal administration of gene therapy vector AAV2-hRPE65v2 (voretigene neparvovec-rzyl) to both eyes via surgical procedures on separate days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Collection of all Adverse Events and Serious Adverse EventsTime frame: up to 5 years
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Children's Hospital of Los Angeles
Los Angeles, California
Bascom Palmer Eye Institute
Miami, Florida
University of Iowa Hospitals & Clinics
Iowa City, Iowa
Massachusetts Eye and Ear Institute
Boston, Massachusetts
Kellogg Eye Center
Ann Arbor, Michigan
Cincinnati Eye Institute
Cincinnati, Ohio
Casey Eye Institute
Portland, Oregon
Children's Hospital of Philadelphia (CHOP)
Philadelphia, Pennsylvania
Scheie Eye Institute
Philadelphia, Pennsylvania
Cullen Eye Institute
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.